Association between treatment with central nervous system stimulants and Raynaud's syndrome in children: A retrospective case-control study of rheumatology patients

Arthritis and Rheumatism

Volumn 58, Issue 2, 2008, Pages 563-566

  Goldman, William ^a   Seltzer, Ryan ^b   Reuman, Peter ^a  

^a AKRON CHILDREN'S HOSPITAL   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; C REACTIVE PROTEIN; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; METHYLPHENIDATE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MCNEMAR TEST; PRESCHOOL CHILD; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; RHEUMATOLOGY; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DEXTROAMPHETAMINE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; RAYNAUD DISEASE; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES;

EID: 39749093724     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23301     Document Type: Article

References (15)

1. Willette RN, Hieble JP, Sauermelch CF. The role of α adrenoceptor subtypes in sympathetic control of the acral cutaneous microcirculation. J Pharmacol Exp Ther 1991;256:599-605.
2. Freedman RR, Sabharal SC, Desai N, Wenig P, Mayes M. Increased α-adrenergic responsiveness in idiopathic Raynaud's disease. Arthritis Rheum 1989;32:61-5.
3. Generini S, Kahaleh B, Matucci-Cerinic M, Pignone A, Lombardi A, Ohtsuka T. Raynaud's phenom enon and systemic sclerosis. Ann Ital Med Int 1996;11:125-31.
4. Bagge U, Branemark PI. White blood cell rheology: an intravital study in man. Adv Microcirc 1977;7:1-17.
5. Grace PA. Ischaemia-reperfusion injury. Br J Surg 1994;81:637-47.
6. Edwards JM, Phinney ES, Taylor LM Jr, Keenan EJ, Porter JM. α2 adrenergic receptor levels in obstructive and spastic Raynaud's syndrome. J Vasc Surg 1987;5:38-45.
7. Graafsma SJ, Wollersheim H, Droste HT, ten Dam MA, van Tits LJ, Reyenga J, et al. Adrenoceptors on blood cells from patients with primary Raynaud's phenomenon. Clin Sci (Lond) 1991;80:325-31.
8. American Academy of Pediatrics Committee on Quality Improvement, Subcommittee on Attention-Deficit/Hyperactivity Disorder. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/ hyperactivity disorder. Pediatrics 2000;105:1158-70.
9. Biederman J. Attention-deficit/hyperactivity disorder: a life-span perspective. J Clin Psychiatry 1998;59 Suppl 7:4-16.
10. Wender PH. Attention-deficit hyperactivity disorder in adults. New York; Oxford University Press, 1995.
11. Miller KJ, Wender EH. Attention deficit/hyperactivity disorder. In: Hoekelman RA, Adam HM, Nelson NM, Weitzman ML, Wilson MH, editors. Primary pediatric care. 4th ed. St. Lous: Mosby; 2001. P. 756-65.
12. Elia J, Ambrosini PJ, Rapoport JL. Treatment of attention deficit hyperactivity disorder. N Engl J Med;1999;340:780-8.
13. Ahmann PA, Waltonen SJ, Olson KA, Theye FW, van Erem AJ, LaPlant RJ. Placebo-controlled evaluation of Ritalin side effects. Pediatrics 1993;91:1101-6.
14. Gunteroch WG, Morgan BC, Harbinson JA. Raynaud's disease in children. Circulation 1967;36:724-9.
15. Singsen BH, Bernstein BH, Kornreich HK, King KK, Hanson V, Tan EM. Mixed connective tissue disease in childhood: a clinical and serologic survey. J Pediatr 1977;90:893-900.